« 'Swish-and-spit' Test Shown Accurate For Head And Neck Cancer | Main | New Research Confirms The Power Of Images In The Brain To Heal The Body »
January 3, 2008
Novel Anticancer Strategy Moves From Laboratory To Clinic
Topics: Medical Science NewsAccording to results of research published in the Jan. 1 issue of Cancer Research on the use of a novel anti-tumor compound in mice, scientists have shown that a chemical inhibitor of all PI-3 kinases (Phosphatidylinositol 3 kinases), modified with a tag that directs the compound to the blood vessels needed by growing tumors, stops the growth of seven types of tumors (in mice). The novel approach represents a distinct strategy: targeting one of the most important "intercept points" for cancer cells.
Tumors send out chemical signals for new blood vessels when they don't have enough oxygen. The authors found that in mice, the compound prevents tumors from growing new blood vessels by inhibiting part of their response to the lack of oxygen. SF1126 also sensitizes human tumors in mice to a chemotherapy agent called taxotere.Continue reading: Novel Anticancer Strategy Moves From Laboratory To Clinic.The authors found that tumor cell lines artificially engineered to be more "addicted" to PI-3 kinase growth signals are more sensitive to the drug. That predicts that some patients' tumors could be more sensitive than others, Dr. Durden says.
Related: The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal.
Posted by Richard at January 3, 2008 1:57 PM
Articles Related to Medical Science News:
